Shares of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) shot up 7.5% during trading on Friday . The stock traded as high as $0.90 and last traded at $0.86. 1,753,743 shares traded hands during mid-day trading, an increase of 258% from the average session volume of 489,758 shares. The stock had previously closed at $0.80.
Several brokerages recently commented on CYCC. Zacks Investment Research cut Cyclacel Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, January 7th. ValuEngine cut Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. Cyclacel Pharmaceuticals has an average rating of “Hold” and a consensus price target of $5.63.
TRADEMARK VIOLATION WARNING: This report was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/4224633/cyclacel-pharmaceuticals-cycc-shares-up-7-5.html.
Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.
Featured Story: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.